

## Selexipag (Uptravi®)

### Place of Service

Hospital Administration  
Office Administration  
Home Infusion Administration  
Outpatient Facility Administration

HCPCS: J3490

### NDC:

66215-0718-01: 1800 mcg single-dose vial

### Condition(s) listed in policy (see criteria for details)

- [Pulmonary arterial hypertension \(PAH\) WHO Group I](#)

**AHFS therapeutic class:** Vasodilating Agents (Respiratory Tract)

**Mechanism of action:** Inhibition Prostacyclin receptor agonist

### **(1) Special Instructions and pertinent Information**

**Covered under the Medical Benefit,** please submit clinical information for prior authorization review.

### **(2) Prior Authorization/Medical Review is required for the following condition(s)**

All requests for Uptravi® (selexipag) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

### Pulmonary arterial hypertension

1. WHO Group I classification, **AND**
2. Member is receiving oral Selexipag, **AND**
3. Member is temporarily unable to take oral medication due to a documented medical reason

### **Covered Doses**

<b>Uptravi tablets dose (mcg) for twice-daily dosing</b>	<b>Corresponding IV Uptravi dose (mcg) for twice-daily dosing</b>
200	225
400	450
600	675
800	900
1000	1125
1200	1350
1400	1575
1600	1800

### **Coverage Period**

Indefinite

**ICD-10:**

127.0 [Primary]; 127.2, 127.89 [Secondary]

**(3) The following condition(s) DO NOT require Prior Authorization/Preservice**

All requests for Upravi® (selexipag) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

**(4) This Medication is NOT medically necessary for the following condition(s)**

Coverage for a Non-FDA approved indication, requires that criteria outlined in Health and Safety Code § 1367.21, including objective evidence of efficacy and safety are met for the proposed indication.

Please refer to the Provider Manual and User Guide for more information.

**(5) Additional Information**

How supplied:

Injection: 1800 mcg (single-use vial)

**Clinical classification of pulmonary hypertension (6<sup>th</sup> World Symposium on Pulmonary Hypertension)**

<b>1 PAH</b>
1.1 Idiopathic PAH
1.2 Heritable PAH
1.3 Drug- and toxin-induced PAH (table 3)
1.4 PAH associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.5 PAH long-term responders to calcium channel blockers
1.6 PAH with overt features of venous/capillaries (PVOD/PCH) involvement
1.7 Persistent PH of the newborn syndrome
<b>2 PH due to left heart disease</b>
2.1 PH due to heart failure with preserved LVEF
2.2 PH due to heart failure with reduced LVEF
2.3 Valvular heart disease
2.4 Congenital/acquired cardiovascular conditions leading to post-capillary PH
<b>3 PH due to lung diseases and/or hypoxia</b>
3.1 Obstructive lung disease
3.2 Restrictive lung disease
3.3 Other lung disease with mixed restrictive/obstructive pattern
3.4 Hypoxia without lung disease
3.5 Developmental lung disorders
<b>4 PH due to pulmonary artery obstructions (table 6)</b>
4.1 Chronic thromboembolic PH
4.2 Other pulmonary artery obstructions
<b>5 PH with unclear and/or multifactorial mechanisms (table 7)</b>
5.1 Haematological disorders

5.2 Systemic and metabolic disorders
5.3 Others
5.4 Complex congenital heart disease

## (6) References

- Abman SH, Hansmann G, Archer, SL, et al. Pediatric Pulmonary Hypertension Guidelines from the American Heart Association and American Thoracic Society. *Circulation* 2015; 132:2037-2099. DOI: 10.1161/CIR.0000000000000329
- AHFS®. Available by subscription at <http://www.lexi.com>
- DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
- Humbert M, Kovacs G, Hoeper M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory distress (ERN-LUNG). *European Heart Journal*, 2022; 43 (38): 3618-3731. <https://doi.org/10.1093/eurheartj/ehac237>
- Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. *Chest* 2019.
- McLaughlin, VV, Archer, SL, Badesch, DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation* 2009;119(16):2250-94.
- Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. *Chest*. 2014;146(2):449-75.
- Uptravi (selexipag) [Prescribing Information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; 10/2021.

## (7) Policy Update

Date of last review: 4Q2023

Date of next review: 4Q2024

Changes from previous policy version:

- No clinical change to policy following routine annual review.

*BSC Drug Coverage Criteria to Determine Medical Necessity  
Reviewed by P&T Committee*

